The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
Abstract
We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10-in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 +/- 9 to 303 +/- 8 mg per deciliter (101 +/- 0.2 to 7.88 +/- 0.2 mmol per liter, mean +/- S.E.M.; p less than 0.001) and serum triglyceride decreased from 137 +/- 18 to 87 +/- 9 mg per deciliter (1.55 +/- 0.20 to 0.98 +/- 0.01 mmol per liter; p less than 0.05). Intermediate-density-lipoprotein (DL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (p less than 0.01, P less than 0.001, and P less than 0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 +/- 0.07 to 0.20 +/- 0.01 microgram per milliliter (P less than 0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meanwhile, the co-administration of a nicotinic acid derivative (niacin) and statin to increase HDL-C levels did not have a suppressive effect on cardiovascular events in the AIM-HIGH653) and HPS2-THRIVE654) studies.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [654]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzymatic determination of total serum cholesterol.
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,845
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,737
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630
Brown, M. S., & Goldstein, J. L. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42221-7 · Cited by 1,210
A colorimetric method for estimating serum triglycerides
Fletcher, M. J. (1968) · Clinica Chimica Acta · doi:10.1016/0009-8981(68)90041-7 · Cited by 1,133
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556
The Familial Hyperlipoproteinemias
Marion, M. S. (1975) · Cited by 528
Plasma High-Density Lipoproteins
Tall, A. R., & SMALL, D. M. (1978) · New England Journal of Medicine · doi:10.1056/nejm197811302992207 · Cited by 500
Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J., & Brown, M. S. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1194 · Cited by 421
Enzyme Topology of Intracellular Membranes
DePierre, J. W., & Ernster, L. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.001221 · Cited by 385
Cholestyramine Promotes Receptor-Mediated Low-Density-Lipoprotein Catabolism
Shepherd, J., Packard, C. J., Bicker, S., Lawrie, T. D. V., & Morgan, H. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005293022202 · Cited by 356
Clofibrate and niacin in coronary heart disease
(1975) · JAMA · doi:10.1001/jama.231.4.360 · Cited by 297
Endo, A., Tsujita, Y., KURODA, M., & Tanzawa, K. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11637.x · Cited by 263
Eisenberg, S., & Levy, R. I. (1975) · Advances in lipid research · doi:10.1016/b978-0-12-024913-8.50008-4 · Cited by 255
KANEKO, O., Yoko, H.-S., & Endo, A. (1978) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1978.tb12380.x · Cited by 249
THE LDL RECEPTOR LOCUS AND THE GENETICS OF FAMILIAL HYPERCHOLESTEROLEMIA
Goldstein, J. L., & Brown, M. S. (1979) · Annual Review of Genetics · doi:10.1146/annurev.ge.13.120179.001355 · Cited by 233
Therapeutic effects of ML-236B in primary hypercholesterolemia
Yamamoto, A., Sudo, H., & Endo, A. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90124-0 · Cited by 231
Inhibition of cell growth by oxygenated derivatives of cholesterol
Chen, H. W., Kandutsch, A. A., & Waymouth, C. (1974) · Nature · doi:10.1038/251419a0 · Cited by 219
Cholestyramine Resin Therapy for Hypercholesteremia
Hashim, S. A. (1965) · JAMA · doi:10.1001/jama.1965.03080170017004 · Cited by 171
Synthesis of ubiquinone and cholesterol in human fibroblasts: Regulation of a branched pathway
Faust, J. R., Goldstein, J. L., & Brown, M. S. (1979) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(79)90074-2 · Cited by 151
REDUCTION OF SERUM-LIPID AND URIC-ACID LEVELS BY AN ORALLY ACTIVE ANDROSTERONE
Oliver, M. F. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92422-4 · Cited by 129
Goldstein, J. L., & Brown, M. S. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90563-x · Cited by 113
Mabuchi, H., Ito, S., Haba, T., Ueda, K., Ueda, R., TATAMI, R., KAMETANI, T., Koizumi, J., Ohta, M., Miyamoto, S., et al. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90199-x · Cited by 112
Self-citationTsujita, Y., Kuroda, M., Tanzawa, K., KITANO, N., & Endo, A. (1979) · Atherosclerosis · doi:10.1016/0021-9150(79)90174-6 · Cited by 112
Cholestyramine in Type II Hyperlipoproteinemia
Levy, R. I., FREDRICKSON, D. S., STONE, N. J., BILHEIMER, D. W., BROWN, W. V., GLUECK, C. J., Gotto, A. M., HERBERT, P. N., KWITEROVICH, P. O., LANGER, T., et al. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-51 · Cited by 99
Receptor-mediated catabolism of homologous low density lipoproteins in cultured pig hepatocytes.
Pangburn, S., Newton, R. S., Chang, C. M., Weinstein, D. B., & Steinberg, D. H. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69612-2 · Cited by 95
Kuroda, M., Tsujita, Y., Tanzawa, K., & Endo, A. (1979) · Lipids · doi:10.1007/bf02533537 · Cited by 81
Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia
Glueck, C. J. (1972) · JAMA · doi:10.1001/jama.222.6.676 · Cited by 75
Studies of Nicotinic Acid Use in Hypercholesteremia
PARSONS, W. B. (1961) · Archives of Internal Medicine · doi:10.1001/archinte.1961.03620050019003 · Cited by 71
Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia
Miettinen, T. A. (1972) · Atherosclerosis · doi:10.1016/0021-9150(72)90066-4 · Cited by 70
Nambudiri, A. M. D., Ranganathan, S., & Rudney, H. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70714-5 · Cited by 60
Goh, E. H., & Heimberg, M. (1979) · Biochemical Journal · doi:10.1042/bj1840001 · Cited by 51
Determination of ubiquinone in serum and liver by high-speed liquid chromatography.
Abe, K., ISHIBASHI, K., OHMAE, M., KAWABE, K., & Katsui, G. (1978) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.24.555 · Cited by 36
Haba, T., Mabuchi, H., Yoshimura, A., Watanabe, A., WAKASUGI, T., Tatami, R., Ueda, K., Ueda, R., KAMETANI, T., Koizumi, J., et al. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110184 · Cited by 30
Self-citationMiller, N. E., & Nestel, P. J. (1975) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1975.tb00451.x · Cited by 16
Fixler, D. E., Watson, J. T., Wheeler, J. M., & Willerson, J. T. (1976) · Circulation · doi:10.1161/01.cir.54.1.26 · Cited by 13
Endo, A. (1980) · Springer eBooks · doi:10.1007/978-1-4612-6071-4_32 · Cited by 4
Research works printed but not linked: 1
- Miettinen, 1974, Eur J Clin Invest, 4, 365
Cited by
Sorted by citations
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 896
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 844
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Metadata
- Authors
- Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R.
- Affiliations
- Kanazawa University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1981-08-27
- Volume
- 305
- Issue
- 9
- Pages
- 478-482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2051105453
- Cited by
- 262
- References
- 41
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 2
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- ML-236B, statins, familial hypercholesterolemia, serum cholesterol, serum triglycerides, lipoproteins, LDL cholesterol, intermediate density lipoprotein, ubiquinone-10
- MeSH terms
- Adult, Aged, Cholesterol, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Lovastatin, Male, Middle Aged, Naphthalenes, Triglycerides, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
